A phase I clinical study of LY03012
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2018
Price : $35 *
At a glance
- Drugs LY 03012 (Primary)
- Indications Pain
- Focus Adverse reactions
- 03 Sep 2018 According to a Luye Pharma Group media release, the National Medical Products Administration (NMPA) approved the clinical trials of LY03012.
- 26 Jun 2018 New trial record
- 19 Jun 2018 According to a Luye Pharma Group media release, clinical applications of the extended release tablets LY03012, a China Class 1.1 new chemical drug, have been formally accepted by the China Food and Drug Administration.